TY - JOUR
T1 - Imaging blood-brain barrier dysfunction
T2 - A state-of-the-art review from a clinical perspective
AU - Moyaert, Paulien
AU - Padrela, Beatriz E.
AU - Morgan, Catherine A.
AU - Petr, Jan
AU - Versijpt, Jan
AU - Barkhof, Frederik
AU - Jurkiewicz, Michael T.
AU - Shao, Xingfeng
AU - Oyeniran, Olujide
AU - Manson, Tabitha
AU - Wang, Danny J. J.
AU - Günther, Matthias
AU - Achten, Eric
AU - Mutsaerts, Henk J. M. M.
AU - Anazodo, Udunna C.
N1 - Funding Information: PM is supported by a doctoral fellowship from Fonds voor Wetenschappelijk Onderzoek (FWO; http://www.fwo.be/en/ ). CM is supported by the Freemasons Foundation, New Zealand. FB is supported by the NIHR Biomedical Research Centre at UCLH. HM is supported by the Dutch Heart Foundation (03-004-2020-T049), the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 Research and Innovation Programme (ASPIRE E!113701), provided by the Netherlands Enterprise Agency (RvO), and the EU Joint Program for Neurodegenerative Disease Research, provided by Netherlands Organisation for Health Research and Development and Alzheimer Nederland (DEBBIE JPND2020-568-106) and the Canadian Institutes of Health Research (CIHR JPND 173743). Publisher Copyright: Copyright © 2023 Moyaert, Padrela, Morgan, Petr, Versijpt, Barkhof, Jurkiewicz, Shao, Oyeniran, Manson, Wang, Günther, Achten, Mutsaerts and Anazodo.
PY - 2023
Y1 - 2023
N2 - The blood-brain barrier (BBB) consists of specialized cells that tightly regulate the in- and outflow of molecules from the blood to brain parenchyma, protecting the brain’s microenvironment. If one of the BBB components starts to fail, its dysfunction can lead to a cascade of neuroinflammatory events leading to neuronal dysfunction and degeneration. Preliminary imaging findings suggest that BBB dysfunction could serve as an early diagnostic and prognostic biomarker for a number of neurological diseases. This review aims to provide clinicians with an overview of the emerging field of BBB imaging in humans by answering three key questions: (1. Disease) In which diseases could BBB imaging be useful? (2. Device) What are currently available imaging methods for evaluating BBB integrity? And (3. Distribution) what is the potential of BBB imaging in different environments, particularly in resource limited settings? We conclude that further advances are needed, such as the validation, standardization and implementation of readily available, low-cost and non-contrast BBB imaging techniques, for BBB imaging to be a useful clinical biomarker in both resource-limited and well-resourced settings.
AB - The blood-brain barrier (BBB) consists of specialized cells that tightly regulate the in- and outflow of molecules from the blood to brain parenchyma, protecting the brain’s microenvironment. If one of the BBB components starts to fail, its dysfunction can lead to a cascade of neuroinflammatory events leading to neuronal dysfunction and degeneration. Preliminary imaging findings suggest that BBB dysfunction could serve as an early diagnostic and prognostic biomarker for a number of neurological diseases. This review aims to provide clinicians with an overview of the emerging field of BBB imaging in humans by answering three key questions: (1. Disease) In which diseases could BBB imaging be useful? (2. Device) What are currently available imaging methods for evaluating BBB integrity? And (3. Distribution) what is the potential of BBB imaging in different environments, particularly in resource limited settings? We conclude that further advances are needed, such as the validation, standardization and implementation of readily available, low-cost and non-contrast BBB imaging techniques, for BBB imaging to be a useful clinical biomarker in both resource-limited and well-resourced settings.
KW - blood-brain barrier dysfunction
KW - diagnostic imaging
KW - magnetic resonance imaging
KW - neurodegeneration
KW - positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=85158910028&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fnagi.2023.1132077
DO - https://doi.org/10.3389/fnagi.2023.1132077
M3 - Review article
C2 - 37139088
SN - 1663-4365
VL - 15
JO - Frontiers in aging neuroscience
JF - Frontiers in aging neuroscience
M1 - 1132077
ER -